4次A轮融资后，这家国产液相色谱质谱企业迎来千万级Pre-B轮融资

Core Viewpoint - Chengdu Keri Technology Co., Ltd. has completed several tens of millions in Pre-B round financing, which will accelerate the improvement and market promotion of its ultra-high-performance liquid chromatography product line, achieving breakthroughs in several core technologies for domestic production [1][2]. Financing History and Technical Breakthroughs - Since its establishment in 2016, Keri Technology has completed multiple rounds of financing, including angel investment in 2018, Pre-A round in 2019, and several A rounds in 2022 and 2024, with total R&D investment exceeding 80 million [3]. - The company has achieved 100% domestic production of core components such as high-pressure infusion pumps and detectors, significantly reducing product BOM costs and avoiding risks from international supply chain fluctuations [3]. Differentiated Market Strategy - Keri Technology has adopted a differentiated market strategy to penetrate the high-end market, which is dominated by overseas brands, by focusing on specific application scenarios [4]. - In the field of wastewater and drug detection, its dual-fish series "online solid-phase extraction two-dimensional liquid chromatography" has served over 30 public security and judicial testing institutions, processing over 50,000 samples annually [4]. Addressing User Experience - To tackle the pain point of insufficient user experience with domestic instruments, Keri Technology has proposed an "open-source software ecosystem" strategy, planning to develop free general chromatography software for non-commercial users, facilitating interoperability among various brands [5]. Outlook for Domestic Substitution - The scientific instrument industry is characterized by long R&D cycles and high technical barriers, and Keri Technology's approach demonstrates the value of long-term commitment [6]. - The company plans to launch a fully automated sample pre-treatment platform, achieving full-process automation from sample to result, while continuing to expand into new scenarios in biomedicine and industrial analysis [6].